Identification of the novel differentiation marker MS4A8B and its murine homolog MS4A8A in colonic epithelial cells lost during neoplastic transformation in human colon

J Michel4,1, K Schönhärl1,4, K Schledzewski1, C Gkaniatsou1, C Sticht1, F Kellert1, F Lasitschka3, C Géraud1, S Goerdt1 and A Schmieder*1

The CD20-homolog Ms4a8a has recently been shown to be a marker for alternatively activated macrophages but its expression is not restricted to hematopoietic cells. Here, MS4A8A/MS4A8B expression was detected in differentiated intestinal epithelium in mouse and human, respectively. Interestingly, no MS4A8B expression was found in human colon carcinoma. Forced overexpression of MS4A8A in the murine colon carcinoma cell line CT26 led to a reduced proliferation and migration rate. In addition, MS4A8A-expressing CT26 cells displayed an increased resistance to hydrogen peroxide-induced apoptosis, which translated in an increased end weight of subcutaneous MS4A8A + CT26 tumors. Gene profiling of MS4A8A + CT26 cells revealed a significant regulation of 225 genes, most of them involved in cytoskeletal organization, apoptosis, proliferation, transcriptional regulation and metabolic processes. Thereby, the highest upregulated gene was the intestinal differentiation marker cytokeratin 20. In conclusion, we show that MS4A8A/MS4A8B is a novel differentiation marker of the intestinal epithelium that supports the maintenance of a physiological barrier function in the gut by modulating the transcriptome and by conferring an increased resistance to reactive oxygen species. The absence of MS4A8B in human colonic adenocarcinomas shown in this study might be a helpful tool to differentiate between healthy and neoplastic tissue.

Cell Death and Disease (2013) 4, e469; doi:10.1038/cddis.2012.215; published online 24 January 2013

Subject Category: Cancer

The mammalian large intestine is a dynamic organ involved in water, electrolyte and vitamin absorption, salvage of nutrients obtained by bacterial fermentation and transportation of feces. For the fulfillment of these physiological processes, the large intestine is equipped with a monolayer of highly specialized columnar epithelial cells lining approximately 2000 cm² of colonic lumen folded in crypts.1 As the colonic mucosa is permanently exposed to damaging mechanical and chemical stress factors, the maintenance of a proper organ function requires rapid renewal and differentiation of mucosal cells. The renewal is achieved by a pool of asymmetrically dividing stem/progenitor cells located in the proliferative compartment of the crypt, which guarantees the preservation of multipotent daughter cells, while generating cells committed to differentiation along the crypt–lumen axis. These cells express cell-cycle-promoting genes and suppress phenotypic markers of mature states.2 Cells intended for differentiation, meanwhile, migrate along the crypt–lumen axis, exit the cell cycle and start expressing specific differentiation markers as villin 2,2 Krüppel-like factor 4,3,4 gelsolin,5 calbinin 3,6 cytokeratin 20 (Krt20)7 or carbonic anhydrase Il2,8 depending on their committed differentiation pathway.13–15 and the TGF-beta signaling pathway.16 Mutations or misregulation in such central regulators predispose to neoplastic transformation, which leads to highly...
proliferative and dedifferentiated tumor cells characterized by chromosomal instability. \(^{18}\)

In this work, we have found the CD20-homolog membrane spanning 4-domains subfamily A (MS4A)8B/MS4A8A expressed in human and murine colonic epithelial cells committed to differentiation outside the colonic crypt, while its expression is lost in human colon carcinoma.

MS4A8B and its murine homolog MS4A8A belongs to the newly defined MS4A/CD20 family of proteins characterized by four transmembrane regions. So far, the exact functions of many MS4A family members are only partially known. They seem to be involved in calcium signaling, modulation of intracellular signaling and differentiation processes of haematopoietic and epithelial cells \(^{19,20}\) by acting as cell-surface signaling molecules and intracellular adapter proteins. \(^{21}\)

In this report, we show that MS4A8A, overexpressed in a colon carcinoma cell line, inhibits proliferation and migration, whereas it increases resistance against hydrogen peroxide (\(H_2O_2\))-induced apoptosis. In addition, Ms4a8a overexpression leads to a specific gene expression profile. Especially Krt20 is upregulated, indicating its important role for the differentiation of colonic epithelial cells along the crypt–luminal axis.

**Results**

**MS4A8B/MS4A8A is expressed in human and murine epithelial cells and is lost in human colon cancer.** In our previous work, the novel CD20-homolog MS4A8A was shown to be expressed by M2 macrophages in parasitic infections and by tumor-associated macrophages in murine mammary carcinoma and malignant melanoma. As a previous gene transcription analysis by Liang et al. \(^{22}\) revealed a strong mRNA expression of Ms4a8a in the murine colon, we used our previously published rabbit polyclonal anti mouse MS4A8A antibody to investigate the physiological expression pattern of MS4A8A in the murine intestinal tract.

Immunohistochemical stainings revealed MS4A8A to be expressed by epithelial cells of the stomach, the small and the large intestine (Figures 1a–c). MS4A8A was thereby not expressed in the stem cell niche of the crypts, but its expression increased along the crypt–luminal axis (Figure 1d).

To investigate whether a similar expression pattern could also be detected in the human gut, a rabbit polyclonal antibody against a specific MS4A8B peptide was generated and used to stain healthy human colon of patients suffering from colon carcinoma. The specificity of the antibody was confirmed by histochemical staining and western blot analysis of transiently transfected MS4A8B+ Caco2 cells (data not shown).

Immunohistochemical analysis showed an MS4A8B expression pattern resembling the one found in mice, with MS4A8B being absent in the crypt bottom, but increasing along the mid part of the crypt–luminal axis and lacking on the innermost luminal side of the colon (Figure 1e). Interestingly, MS4A8B was either absent or detectable very faint in the colon carcinoma of these patients (Figure 1f). Western blot analysis of protein extracts from healthy colon and colon carcinomas confirmed the loss of MS4A8B in the neoplastic tissue (Figure 1g).

**Overexpression of Ms4a8a in the murine colon carcinoma cell line CT26 reduces migration and proliferation, whereas resistance to apoptosis was increased.** The fact that both MS4A8A and MS4A8B expression in murine and human colon increases along the crypt–surface axis and is lost during neoplastic transformation pointed to an association of MS4A8A/MS4A8B with differentiation processes in the colon. As it is known that during differentiation colonic epithelial cells downregulate genes involved in the cell cycle and upregulate genes associated with the cytoskeleton, we were interested whether MS4A8A expression exerted some effects on migration and proliferation of colonic epithelial cells. In addition, the effect of Ms4a8a on resistance to apoptosis was measured. For this purpose, two Ms4a8a-transfected (CT26-#14 and CT26-#20) and two control empty vector (EV)-transfected (CT26-EV1 and CT26-EV2) CT26 colon carcinoma cell clones were generated. The Ms4a8a expression level of the clones was verified by immunohistochemistry (Figure 2a), fluorescence-activated cell sorter (FACS) analysis (Figure 2b), quantitative reverse transcriptase–PCR (Figure 2c) and western blot analysis (Figure 2d).

To test whether MS4A8A has an influence on cell motility, a scratch was set in the cell monolayer of confluent transgenic cells, pre-treated with mitomycin. The migration rate of the cells into the scratch was assessed by regular 2 h scratch measurements until complete closure. The Ms4a8a+ CT26 clones #14 and #20 migrated significantly slower into the artificial scratch than the EV clones EV1 and EV2 (Figure 3a), with a complete closure of the scratch achieved after 10 h by CT26-EV1 and CT26-EV2 versus 12 h by CT26-#14 and CT26-#20.

The hypothesis that MS4A8A overexpression also interfere with cell proliferation was investigated by the 5-bromo-2-deoxy-uridine (BrdU) incorporation method. FACS analysis of CT26 transfectants revealed a statistically significant reduction in BrdU incorporation of Ms4a8a+ CT26 clones #14 and #20 migrated significantly slower into the artificial scratch than the EV clones EV1 and EV2 (Figure 3a), with a complete closure of the scratch achieved after 10 h by CT26-EV1 and CT26-EV2 versus 12 h by CT26-#14 and CT26-#20.

To test whether MS4A8A-mediated reduction of migration and proliferation rates coincide with a higher rate of cell mortality, we analyzed the resistance of transgenic CT26 clones to apoptosis by exposing them to 2.5-mm \(H_2O_2\). Surprisingly, after 3 h 77.2% of CT26-EV1 and 65.1% of CT26-EV2 were apoptotic, while the apoptosis rate was only 39.2% in CT26-#14 and 38.3% in CT26-#20 (Figure 3c). The differences in apoptosis between MS4A8A+ clones versus controls were statistically significant.

Our results indicate that overexpression of MS4A8A has an inhibitory effect on proliferation and migration of transgenic CT26 cells but seems to increase resistance to apoptotic stimuli.
Subcutaneous injection of MS4A8A+ CT26 clones in the mouse flank leads to an increased tumor end weight attributable to a higher resistance to apoptosis. To test whether the reduced migration and proliferation or the higher resistance to apoptosis assessed in MS4A8A+ CT26 clones in vitro translates in a differential tumor growth in vivo, a total of $3 \times 10^5$ transgenic CT26-#14 and CT26-EV1 tumor cells were injected in the right mouse flank. In vivo, MS4A8A+ CT26 tumors reached a significantly higher relative tumor end weight after 14 days (Figure 4a). To confirm this result independently, the experiment was repeated with CT26-#20 and CT26-EV2. Even after a growth period of 21 days, the end weight of MS4A8A+ tumors exceeded the size of controls significantly (Figure 4b).

To test whether the apoptosis resistance measured for MS4A8A+ CT26 clones in vitro is still detectable in solid tumors in vivo, single-cell apoptosis rate was assessed by staining representative cryosections of CT26-#14 and CT26-EV2 tumors with a rabbit anti-mouse caspase 3 antibody. In CT26-#14 tumors, a mean of 1.8 caspase 3-positive cells per $40 \times$ high power field was counted, while in CT26-EV2, the rate of caspase 3-positive cells was significantly higher with a mean of 27.1. Necrotic areas correlated with the total tumor weight and were excluded from this analysis (Figure 4c).

Therefore, a higher resistance of MS4A8A+ CT26 cells to apoptosis measured in vitro and in vivo could be one relevant factor causing the increased tumor end weight.

MS4A8A+ CT26 cells are characterized by an overexpression of Krt20 and other genes. A gene microarray analysis was performed to identify the molecular program underlying the effects of MS4A8A+ CT26 cells on proliferation, migration and apoptosis.

The comparison of the gene expression profile of CT26-#14 and CT26-#20 with CT26-EV1 and CT26-EV2 showed a significant regulation of 225 genes, thereof 148 genes were upregulated and 77 genes were downregulated (Table 1). Several well-known genes involved in cytoskeletal

---

**Figure 1** The homologs MS4A8A/MS4A8B are expressed in a similar manner in human and murine colonocytes, with an increase in expression along the crypt–luminal axis. The expression is restricted to normal colonic mucosa and lost in colon cancer. Histochemical stainings of acetone-fixed cryostat sections of (a) murine stomach, (b) small intestine and (c) large intestine with rabbit anti-mouse polyclonal MS4A8A antibody. Positive cells appear in red. Bars = 100 μm. (d) Image magnification of the crypts of murine large intestine stained with rabbit-anti mouse polyclonal MS4A8A antibody. Positive cells appear in red. Bars = 100 μm and 50 μm as indicated. (f) Western blot analysis of protein extracts of tissue from healthy colon and colon carcinoma of three independent patients (P1–3) stained with rabbit anti-human polyclonal MS4A8B antibody. To ensure identical protein loading, the same samples were stained with rabbit anti-mouse/human GAPDH antibody; n = 3.
organization, apoptosis, proliferation, differentiation and metabolic processes were found (Table 1). Beside krt20 only aldo-keto reductase family 1 member C18 showed a remarkable upregulation with a fold change $4^{10}$. To verify the reliability of these results on protein and mRNA level, the differential expression levels of krt20 in CT26-#14, CT26-#20, CT26-EV1 and CT26-EV2 colon carcinoma cells were confirmed by quantitative reverse transcriptase–PCR (Figure 5a) and western blot (Figure 5b).

To compare the expression of KRT20, a well-known differentiation marker in the colon, with the one found for MS4A8A, healthy murine colon was stained. Interestingly, MS4A8A and KRT20 showed a similar expression profile in the upper part of the crypt–luminal axis, suggesting a co-dependency in the gut (Figures 5c and d).

**Discussion**

In our previous work, MS4A8A was found to be expressed by typical M2 macrophages in murine tumor tissue and parasitic infections. Forced overexpression of MS4A8A in a macrophage-like cell line led to the induction of a subset of genes involved in immune regulation but had no effect on proliferation or cell death.\(^{19,23}\)

In this study, we show that not only MS4A8A is not restricted to macrophages but that it is also found in epithelial cells of the gastrointestinal tract. Thereby, MS4A8A as well as the human homolog MS4A8B were not detected in the stem cell niche of the gut but in differentiating cells. In addition, the expression of MS4A8B was lost in dedifferentiated human adenocarcinoma. These findings classify MS4A8A/MS4A8B as a novel marker for differentiation in the gut.

In the intestine, differentiation processes are tightly regulated by the combinational effect of positive and negative transcriptional regulatory networks and transcription factors such as HNF4\(\alpha\), CDX2, HNF1\(\alpha\) and many others.\(^{24}\) To identify known transcription factor-binding sites in the predicted Ms4a8a promoter, a bioinformatic analysis using MatInspector software was performed, which revealed two CDX2, one HNF1\(\alpha\), but no HNF4\(\alpha\)-binding sites (data not shown).
gut, CDX2 and HNF1α expression increases along the crypt–surface axis thereby inducing a rapid progression from proliferation to cell-cycle arrest. As overexpression of MS4A8A in CT26 cells leads to a statistically significant inhibition of proliferation and shows a similar expression pattern as CDX2 and HNF1α, a possible transcriptional regulation of MS4A8A/MS4A8B by CDX2 or HNF1α is imaginable.

Involvement of MS4A proteins in cell proliferation has already been described for CD20 (MS4A1) in B cells, MS4A3 in a human monocyte like cell line and for MS4A4B in T cells. Although CD20 seems to regulate cell-cycle progression by its regulatory function on transmembrane Ca²⁺ conductance, MS4A3 does this by binding to cyclin-dependent kinase-associated phosphatase–cyclin-dependent kinase 2 complexes causing a G0/G1 cell-cycle arrest. For MS4A4B, the mechanism underlying the cell-cycle arrest in T cells at the G0/G1 remains to be fully determined, but its overexpression correlates with an increase in cell-cycle inhibitors and a decrease in cyclins A and B. How MS4A8A affects proliferation and migration in CT26 colon carcinoma cells still warrants clarification, as in contrast to many other MS4A proteins, MS4A8A lacks an intracytoplasmatic signaling sequence, which excludes direct pathway activation. The overall structure of MS4A8A, however, suggests a possible adaptor function as has been described for MS4A4B and MS4A6B. Using a yeast split–ubiquitin screen, Howie et al. provided proof of a lateral association within the MS4A family members and with other co-stimulatory molecules as GITR (glucocorticoid-induced TNFR family-related gene). A cluster formation of MS4A4B with GITR was able to lower the threshold for GITR activation in regulatory T cells. In a similar manner, MS4A8A could interact with other surface receptors or other MS4A family members. In the gastrointestinal tract, several members of the MS4A family like Ms4a4, Ms4a6, Ms4a7, Ms4a10, Ms4a11 and Ms4a12 have been described. However, protein data are available only for MS4A12. On cellular level, MS4A8A/MS4A8B and MS4A12 both show a luminal distribution in a healthy colon, which makes a direct interaction possible.

MS4A8A overexpression in CT26 colon carcinoma cells induced a special gene signature comprising genes involved in cytoskeletal organization, apoptosis, proliferation, transcriptional regulation and, in particular, metabolic processes. This supports the hypothesis that MS4A8A might be involved in differentiation processes of intestinal epithelial cells as during differentiation along the crypt–surface axis upregulation of genes important for the cytoskeleton, digestive enzymes and transport proteins occur. The highest regulated gene by MS4A8A was Krt20, which was confirmed on the mRNA and protein level and showed an expression that parallels that of MS4A8A in the colon in vivo. KRT20 is a type I keratin and a well-known intestinal differentiation marker. It belongs to the keratin family, which provides important...
MS4A8A supports differentiation in colon
J Michel et al

MS4A8A-transfected CT26 cells display an increased resistance to H$_2$O$_2$-induced apoptosis. Whether this effect and the effect on proliferation and migration are attributable directly to MS4A8A or rather to its regulated genes in particular KRT20 needs further evaluation.

Overall, the expression of MS4A8A during differentiation of intestinal epithelial cells along the crypt–luminal axis seems to support the integrity of the intestinal barrier function by modulating the transcriptome and conferring the intestinal cells an increased resistance to reactive oxygen species present in the gastrointestinal lumen. As we have shown that MS4A8B in humans is lost in colon carcinomas, MS4A8B in the future might also be used as marker to distinguish neoplastic from healthy tissue, but this needs further evaluation of tissue samples from colon carcinoma patients. Findings presented in this study might therefore help to further understand physiological and pathophysiological processes in the murine and human intestinal tract.

Materials and Methods

Mice. BALB/c wild type mice were purchased from Eleviser Janvier. Animal experimental protocols were approved by the animal ethics committee (Regierungspräsidium Karlsruhe, Az: 35-9185.81/G-115/07).

Human specimen. The use of human tissue for study purposes was approved by the local Ethics Committee at the University Hospital Heidelberg, Germany. Gut tissue samples were derived from surgical specimens of patients with established adenocarcinoma of the colon (Department of Surgery, University Hospital Heidelberg; informed consent was given by the patients). No patient received neoadjuvant therapy before operation. Diagnosis was made in accordance with clinical and conventional histopathological criteria. Tissue samples were obtained from macroscopically tumorous as well as macroscopically noninvolved gut regions and snap-frozen in liquid nitrogen. Subsequently, all samples included in the study underwent expert histopathological examination (LF) before further analysis. Clinical findings of the patients are provided in Table 2.

Materials/antibodies. The following reagents were used: rabbit polyclonal IgG anti GAPDH (glyceraldehyde-3-phosphate dehydrogenase; Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-mouse caspase 3 (Cell Signal Technology, Boston, MA, USA), monoclonal mouse anti-human/mouse Krt20 (clone Ks20.8; Dako, Glostrup, Denmark), guinea pig anti-mouse Krt20, goat anti-rabbit IgG-horseradish peroxidase (Santa Cruz Biotechnology), mouse BD Fc Block (BD Biosciences, Heidelberg, Germany), anti-mouse BrdU FITC and mouse IgG Isotype FITC (Sigma-Aldrich, Taufkirchen, Germany).

Custom-made anti-mouse MS4A8A serum was produced as previously described. Custom-made anti-MS4A8B serum was produced by immunizing rabbits with a synthetic peptide (234PVTSPPSYSSEIQANK250) representing the C-terminal part of MS4A8B (Peptide Speciality Laboratories, Heidelberg, Germany). Antibody specificity was confirmed by immunohistochemistry and western blot analysis of transient MS4A8B-transfected Caco2 cells and human gut.

Cells. CT26 colon carcinoma cells (ATCC CRL-2638) and Caco2 cells (ATCC HTB-37) were obtained from American Type Culture Collection. CT26 were cultivated with RPMI media with 10% FCS and 100 IU penicillin, 100 $\mu$g/ml streptomycin. Caco2 were cultivated with DMEM media with 10% FCS and 100 IU penicillin, 100 $\mu$g/ml streptomycin (all cell culture media Biochrom, Berlin, Germany). Authentication of cell lines was assured by regular morphology checks and growth curve analyses. Cells were regularly tested for mycoplasma infection by PCR.

Generation of Ms4a8a-transfected CT26 cells. A recombinant Ms4a8a cDNA was amplified by PCR (primer: Ms4a8a-Spel-fw: 5’ATC GAATTCCATAGTAGCAAAGAGTTGGGAACCGGAGCAAGA3’ and Ms4a8a-Not-rv: 5’ATATGCGGCCGCTAGAGCATCTTTAT3’) from Ms4a8a cDNA RZPDp881B0000D (IMAGE ID 905005), purified on agarose gel and subcloned into pEG202 vector (BD Biosciences, Heidelberg, Germany). Transfection of CT26 cells with the resulting constructs was performed in 24-well plates using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Transfected cells were selected with 500 $\mu$g/ml Hygromycin B (BD Biosciences, Heidelberg, Germany) and screened for antibody expression by Western blot analysis. Clones expressing high levels of Ms4a8a were selected for further analysis.

Figure 4 MS4A8A overexpression in CT26 cells leads to a higher tumor end weight in vivo by conferring increased resistance to apoptosis. (a) Relative end weights of 14 days old subcutaneously injected CT26-#14 or CT26-EV1 tumors. Relative end weights of 21 days old subcutaneously injected CT26-#20 or CT26-EV2 tumors. The relative weight (a and b) is calculated by setting the end weight of CT26-EV1/2 as 1; $n = 5$. (c) Number of caspase 3-positive cells in subcutaneously injected CT26-#14 and CT26-EV2 tumors ascertainment by counting positive-stained cells of five randomly chosen × 40 high power fields of each tumor; $n = 3$. Mechanical support for cells and protects them from apoptosis and non-mechanical forms of injury by interacting with different adaptor molecules and cell receptors.

Cell Death and Disease
after digestion with SpeI and Nol restriction enzymes into the expression vector pEF6/V5-His Top (Invitrogen, Carlsbad, CA, USA) according to standard molecular biology protocols. After confirming sequence identity, we transfected each clone with recombinant Ms4a4a or Ms4a4b expression vectors. As a negative control, two vector-transfected CT26 clones (CT26-EV1 and CT26-EV2) were selected under parallel culture conditions. The transfected cells were grown in a 10% CO2 atmosphere at 37°C in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma-Aldrich) enriched with a protease inhibitor cocktail (Roche Diagnostics).

Quantitative reverse transcriptase–PCR analysis. RNA was extracted from all cell lines and used for cDNA synthesis. Real-time quantitative PCR analysis with the LightCycler system (Roche Diagnostics) was performed with SYBR Green (Roche Diagnostics) as described. The fold change was calculated according to the standard curve method.

Immunohistochemistry. Cryostat sections of murine and human colon and human colon adenocarcinoma as well as cells grown on glass cover slips were air-dried and acetone-fixed. Blocked with 2% BSA in PBS and incubated with the appropriate primary antibody respectively, followed by incubation with the appropriate secondary antibody and horseradish peroxidase-labeled antibody. For signal detection, SuperSignal West Dura substrate (Pierce, Rockford, IL, USA) was used. Pictures were taken with a Olympus BX51 microscope.

Western blot analysis. Proteins were obtained by treating whole cells or tissue with RIPA-P buffer (150 mM NaCl, 15% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris/HCl [pH 8.0], 10 mM MnF, 1 mM Na2-EDTA, 2 mM EDTA) and subjected to SDS polyacrylamide gel electrophoresis. After blotting onto nitrocellulose (Schleicher & Schuell) membranes were incubated for 2 h with the appropriate antibody, followed by incubation with the appropriate secondary horseradish peroxidase-labeled antibody. For signal detection, the chemiluminescence substrate (Pierce Biotechnology, Rockford, IL, USA) was used.

Quantitative reverse transcriptase–PCR analysis. For RNA extraction, the Total RNA kit (Qiagen, Valhalla, NY, USA) was used according to the manufacturer’s instructions. For cDNA synthesis, 1 µg of RNA was reverse-transcribed using the Superscript II reverse transcriptase (Invitrogen). Real-time quantitative PCR analysis with the LightCycler system (Roche Diagnostics) was performed with SYBR Green (Roche Diagnostics) as described. The fold change was calculated according to the standard curve method.
RNA was used for reverse transcription with RevertAid H Minus M-MuLV Reverse Transcriptase (Fermentas, St Leon-Rot, Germany) using Oligo (dT) 18 Primer following the manufacturer’s instructions.

For quantitative reverse transcriptase–PCR, 1 µl of cDNA was amplified using SyBRGreen PCR Master Mix (Applied Biosystems Inc., Carlsbad, CA, USA) under standard conditions with an MX3000P sequence detection system (Stratagene, La Jolla, CA, USA). All primers used are listed in Supplementary Table S1.

**FACS analysis.** For FACS analysis, 5 × 10⁶ cells were washed three times with PBS one time and fixed with 4% paraformaldehyde. First antibody (MS4A8A or MS4A8B) was incubated for 1 h on ice. After washing with PBS, the secondary antibody (goat anti-rabbit FITC) was added. Fluorescence labeled cells were analyzed with FACS-CantoII (BD Biosciences, Heidelberg, Germany). Results were analyzed with the WinMDI Version 2.8 software (www.winmdi.software.informer.com).

**Table 2** Background information on human adenocarcinomas

| Tissue                  | Gender | Age | Diagnosis           | TNM                               | Grading |
|-------------------------|--------|-----|---------------------|-----------------------------------|---------|
| Cecum                   | M      | 67  | Adenocarcinoma      | pT2, pNO(0/13), pMx, L0, V0       | G2      |
| Cecum                   | M      | 58  | Adenocarcinoma      | pT1, pNO(0/28), pMx, L0           | G2      |
| Colon descendens        | M      | 59  | Adenocarcinoma      | pT3, pNO(0/12), pMx, L0           | G2      |
Proliferation assay. In all, 1 × 10⁶ cells were seeded in a six-well plate, allowed to grow until 70–80% confluence. To measure DNA synthesis as indicator for cell division 25 μg/ml BrdU (from Sigma-Aldrich) was added to the cell culture for 1 h. After washing, free BrdU cells were trypsinized, fixed with 70% ethanol and denatured with 2M HCl. After denaturation, the cells were neutralized with 0.1 M sodiumborat buffer and incubated with FITC-labeled mouse anti-BrdU or a mouse IgG isotype control. Fluorescence was detected by flowcytometry (FACS Canto II) and afterwards analyzed with WinMDI Version 2.8 software.

Apoptosis assay with crystal violet. In all, 7 × 10⁵ cells were seeded in a 96-well plate (covered with 0.2% gelatin in H₂O) and incubated until complete adhesion of cells. Thereafter, 10 μl of FITC-labeled annexin V and 10 μl 7-AAD (both from Biolegend) were added to the cell culture and incubated for 15 min at 37°C. Fluorescence was detected by flowcytometry (FACS Canto II) and afterwards analyzed with WinMDI Version 2.8 software.

Scratch migration assay. In all, 2.5 × 10⁵ cells were grown to 100% confluence on a 12-well plate coated with 0.2% gelatin. After a pre-treatment with 10 ng/ml mitomycin C (Carl Roth GmbH, Karlsruhe, Germany) for 45 min to inhibit proliferation, a scratch was set with a pipette tip in the cell monolayer, and the floating cells were washed away by several changes of media. Scratches were photographed every 2 h until complete closure. For each time point, five pictures of each scratch were randomly taken. In each picture, five measuring bars were set using Image J software (freeware, http://rsbweb.nih.gov/ij/). Results are shown as percentages with 100% defined as a complete wound closure.

Caspase activity. A representative crystalst stain of three CT26-k14 and three CT26-REV2 tumors was stained as previously described with anti-caspase 3 and 2 antibodies and the appropriate horseradish peroxidase-labeled secondary antibody. Five pictures of each tumor were randomly taken and the number of caspase 3-positive cells was counted. Necrotic areas were excluded from the cell count.

cDNA microarray analysis and statistical procedures. For microarray analysis, 10 × 10⁶ MscA48A-transfected and EV-transfected CT26 cells were incubated with RPMI, 10% FCS, 100 IU penicillin, 100 μg/ml streptomycin for 48 h. Gene expression profiling was performed using mouse genome 430 2.0 DNA arrays (Affymetrix, Santa Clara, CA, USA) according to the recommendations of the manufacturer. A Custom CDF Version 14 with Entrez-based gene definitions was used to annotate the arrays. Differential gene expression was analyzed based on loglinear mixed model ANOVA using a commercial software package SAS JMP7 Genomics, version 4 from SAS (SAS Institute, Heidelberg, Germany). A false-positive rate of α = 0.05 with FDR correction was taken as the level of significance. Full data are deposited in the Gene Expression Omnibus database.

Statistical analysis. All data were statistically evaluated by using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA). Statistical Significance was verified by using one-way ANOVA and Bonferroni as post test. For the scratch migration assay, area under the curve was calculated and statistically evaluated using one-way ANOVA and Bonferroni post test. Level of significance was indicated by asterisks (**P < 0.01; *P < 0.05; and *P < 0.05). Error bars show S.E.M. of each experiment. All experiments were performed at least in triplicates.

Conflict of Interest All authors declare no conflict of interest.

Acknowledgements. This work was supported, in part, by grants of Deutsche Forschungsgemeinschaft SFB938, project H to SG and project ZZ to FL. We thank Christina Schmuttermair and Evelyn Exner for expert technical assistance.

1. Sandlie GI. Salt and water absorption in the human colon: a modern appraisal. Gut 1998; 43: 294–299.
2. Papetti M, Augenlicht LH, MYBL2: a link between proliferation and differentiation in maturing colon epithelial cells. J Cell Physiol 2010; 226: 785–791.
3. Shie JL, Chen ZY, O'Brien MJ, Pestell RG, Lee ME, Tseng CC. Role of gut-enriched Kruppel-like factor in colonic cell proliferation and differentiation. Am J Physiol Gastrointest Liver Physiol 2000; 279: G806–G814.
4. Katz JP, Perrault N, Goldstein BG, Lee CS, Labosky PA, Yang VW et al. The zinc-finger transcription factor NORE is required for terminal differentiation of goblet cells in the colon. Development 2002; 129: 2619–2629.
5. Lueck A, Brown D, Kwiatkowski DJ. The actin-binding proteins severin and gelosin are both highly expressed but differentially localized in kidney and intestine. J Cell Sci 1999; 111(Pt 24): 3633–3643.
6. Colot S, Remaglio B, Lambert M, Cluzeaud F, Porteu A, Vandavelle A et al. Intestinal expression of the calbindin-D9K gene in transgenic mice. Requirement for a Cdx2-binding site in a distinct activator region. J Biol Chem 1998; 273: 31939–31946.
7. Chan CW, Wong NA, Liu Y, Bicknell D, Turley H, Hollins L et al. Gastrointestinal differentiation marker Cytookeratin 20 is regulated by homeobox gene CDX1. Proc Natl Acad Sci USA 2009; 106: 215: 411–420.
8. Lionnet G, Selong O, Wistrand PJ. Amount and distribution of carbonic anhydrases CA I and CA II in the gastrointestinal tract. Gastroenterology 1985; 88 (5 Pt 1): 1151–1161.
9. Mariadason JM, Nicholas C, L’Italien KE, Zhuang M, Smartt HJ, Heerdt BG et al. Gene expression profiling of intestinal epithelial cell maturation along the crypt-villus axis. Gastroenterology 2005; 128: 1081–1088.
10. Hall PA, Coates PJ, Ansari B, Hopwood D. Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. J Cell Sci 1994; 107(Pt 12): 3569–3577.
11. Olsen AK, Boyd M, Danielson ET, Troelsen JT. Current and emerging approaches to define intestinal epithelium-specific transcriptional networks. Am J Physiol Gastrointest Liver Physiol 2010; 322: 2277–2286.
12. Jensen J, Pedersen EE, Galante P, Hald J, Heller RS, Ishibashi M et al. Control of endodermal endocrine development by Hes-1. Nat Genet 2000; 24: 36–44.
13. Battle E, Henderson JT, Bechget H, van den Bom MM, Sancho E, Huls G et al. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB2/EphrinB2. Cell 2002; 111: 251–263.
14. Kizner KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1998; 91: 159–170.
15. Pinto D, Clevers H, Wnt, stem cells and cancer in the intestine. Bio Cell 2005; 97: 185–196.
16. Barros R, Pereira B, Duluc I, Azevedo M, Mendes N, Camilo V et al. Key elements of the BMP/SMAD pathway co-localize with CDX2 in intestinal metabolism and regulate CDX2 expression in human gastric cell lines. J Pathol 2008; 215: 411–420.
17. Pino MS, Kikuchi H, Zeng M, Heriazi MT, Sperduti I, Berger D et al. Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells. J Cell Physiol 2001; 188: 275–297.
18. Barros R, Pereira B, Duluc I, Azevedo M, Mendes N, Camilo V et al. Calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells. J Cell Physiol 2001; 188: 275–297.
19. Schmieder A, Schledzewski K, Michel J, Tuckermann JP, Tome L, Sticht C et al. Synergistic activation by p38MAPK and glucocorticoid signaling mediates induction of M2-like tumor-associated macrophages expressing the novel CD20 homolog MS4A4A. J Immunol 2011; 129: 122–133.
20. Kosowski M, Sahn U, Dahne K, Huber C, Tureo O, MS4A12 is a colon-selective store-operated calcium channel promoting malignant cell processes. Cancer Res 2008; 68: 3458–3466.
21. Kutok JL, Yang X, Folkert R, Adra CN. Characterization of the expression of HTM4 (MS4A3), a cell cycle regulator, in human peripheral blood cells and normal and malignant tissues. J Cell Mol Med 2011; 15: 86–92.
22. Liang Y, Tedder TF. Identification of a CD20+-FcεRIαRbeta- and HTM4-related gene family: sixteen new MS4A family members expressed in human and mouse tissues. Genomics 2001; 72: 119–127.
23. Schmieder A, Schledzewski K, Michel J, Tuckermann JP, Tome L, Sticht C et al. Synergistic activation by p38MAPK and glucocorticoid signaling mediates induction of M2-like tumor-associated macrophages expressing the novel CD20 homolog MS4A4A. J Immunol 2011; 129: 122–133.
24. Kutok JL, Yang X, Folkert R, Adra CN. Characterization of the expression of HTM4 (MS4A3), a cell cycle regulator, in human peripheral blood cells and normal and malignant tissues. J Cell Mol Med 2011; 15: 86–92.
30. Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca\textsuperscript{2+} conductance found constitutively in B lymphocytes. *J Cell Biol* 1993; 121: 1121–1132.

31. Howie D, Nolan KF, Daley S, Butterfield E, Adams E, Garcia-Rueda H et al. MS4A4B is a GITR-associated membrane adapter, expressed by regulatory T cells, which modulates T cell activation. *J Immunol* 2009; 183: 4197–4204.

32. Ishibashi K, Suzuki M, Sasaki S, Imai M. Identification of a new multigene four-transmembrane family (MS4A) related to CD20, HTm4 and beta subunit of the high-affinity IgE receptor. *Gene* 2001; 264: 87–93.

33. Halbleib JM, Saaf AM, Brown PO, Nelson WJ. Transcriptional modulation of genes encoding structural characteristics of differentiating enterocytes during development of a polarized epithelium in vitro. *Mol Biol Cell* 2007; 18: 4261–4278.

34. Coulombe PA, Wong P. Cytoplasmic intermediate filaments revealed as dynamic and multipurpose scaffolds. *Nat Cell Biol* 2004; 6: 699–706.

**Cell Death and Disease** is an open-access journal published by Nature Publishing Group. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/

Supplementary Information accompanies the paper on Cell Death and Disease website (http://www.nature.com/cddis)